Proactive Investors - Run By Investors For Investors

OptiBiotix Health signs production and supply agreement for weight loss product

Italy’s Nutrilinea will formulate and distribute SlimBiome Medical
OptiBiotix Health signs production and supply agreement for weight loss product
SlimBiome Medical carries a CE Mark, which provided European regulatory sign-off for the product, while it is also recognised as a medical device

OptiBiotix Health plc (LON:OPTI) has agreed a production, packaging and supply agreement for its CE Marked weight management product.

Italy’s Nutrilinea will formulate and distribute SlimBiome Medical, which also has medical device status, in boxes of 30 single sachet doses for sale across its network and the UK firm’s growing list of partners.

READ: OptiBiotix surges as SlimBiome granted CE mark and medical device status

No financial details were given; however, Optibiotix said it wanted to “maximise the return” for both parties.

Chief executive Stephen O’Hara said: “We chose Nutrilinea due to their industry reputation, extensive European network and expertise in manufacture of high value food and medical products for Europe and the USA.

“We believe partners like Nutrilinea provide the best opportunity of building SlimBiome Medical into a global brand.

“We see CE marking and medical device registration as an exciting extension of SlimBiome from food products into high value medical products in consumer healthcare and pharmaceutical markets which we hope will contribute substantive revenues to OptiBiotix's growth in the months and years ahead."

View full OPTI profile View Profile

OptiBiotix Health PLC Timeline

Related Articles

CBD oil
November 15 2018
The company’s technology creates nano-scale emulsion mixtures that allow fluids to mix that normally don’t mix, such as CBD oil and water
pills
April 12 2019
The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use
Weight loss
January 07 2019
A deal with Indian firm Zeon Lifesciences in January is the ninth deal the firm has secured for the weight loss product

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use